|
1
|
Tokuyama M and Mabuchi T: New treatment
addressing the pathogenesis of psoriasis. Int J Mol Sci.
21(7488)2020.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Griffiths CE and Barker JN: Pathogenesis
and clinical features of psoriasis. Lancet. 370:263–271.
2007.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Nestle FO, Kaplan DH and Barker J:
Psoriasis. N Engl J Med. 361:496–509. 2009.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Parisi R, Symmons DPM, Griffiths CE and
Ashcroft DM: Identification and Management of Psoriasis and
Associated ComorbidiTy (IMPACT) project team. Global epidemiology
of psoriasis: A systematic review of incidence and prevalence. J
Invest Dermatol. 133:377–385. 2013.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Rachakonda TD, Schupp CW and Armstrong AW:
Psoriasis prevalence among adults in the United States. J Am Acad
Dermatol. 70:512–516. 2014.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Parisi R, Iskandar IYK, Kontopantelis E,
Augustin M, Griffiths CEM and Ashcroft DM: Global Psoriasis Atlas.
National, regional, and worldwide epidemiology of psoriasis:
Systematic analysis and modelling study. BMJ.
369(m1590)2020.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Michalek IM, Loring B and John SM: A
systematic review of worldwide epidemiology of psoriasis. J Eur
Acad Dermatol Venereol. 31:205–212. 2017.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Dand N, Mahil SK, Capon F, Smith CH,
Simpson MA and Barker JN: Psoriasis and Genetics. Acta Derm
Venereol. 100(adv00030)2020.PubMed/NCBI View Article : Google Scholar
|
|
9
|
O'Rielly DD, Jani M, Rahman P and Elder
JT: The genetics of psoriasis and psoriatic arthritis. J Rheumatol.
(Suppl 95):46–50. 2019.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Weiss G, Shemer A and Trau H: The Koebner
phenomenon: Review of the literature. J Eur Acad Dermatol Venereol.
16:241–248. 2002.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Malhotra SK and Mehta V: Role of stressful
life events in induction or exacerbation of psoriasis and chronic
urticaria. Indian J Dermatol Venereol Leprol. 74:594–599.
2008.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Basavaraj KH, Ashok NM, Rashmi R and
Praveen TK: The role of drugs in the induction and/or exacerbation
of psoriasis. Int J Dermatol. 49:1351–1361. 2010.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Fry L and Baker BS: Triggering psoriasis:
The role of infections and medications. Clin Dermatol. 25:606–615.
2007.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Higgins E: Alcohol, smoking and psoriasis.
Clin Exp Dermatol. 25:107–110. 2000.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Armstrong AW, Harskamp CT and Armstrong
EJ: The association between psoriasis and obesity: A systematic
review and meta-analysis of observational studies. Nutr Diabetes.
2(e54)2012.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Balato N, Di Costanzo L, Patruno C, Patrì
A and Ayala F: Effect of weather and environmental factors on the
clinical course of psoriasis. Occup Environ Med.
70(600)2013.PubMed/NCBI View Article : Google Scholar
|
|
17
|
López-Estebaranz JL, Sánchez-Carazo JL and
Sulleiro S: Effect of a family history of psoriasis and age on
comorbidities and quality of life in patients with moderate to
severe psoriasis: Results from the ARIZONA study. J Dermatol.
43:395–401. 2016.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Duffy DL, Spelman LS and Martin NG:
Psoriasis in Australian twins. J Am Acad Dermatol. 29:428–434.
1993.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Trembath RC, Clough RL, Rosbotham JL,
Jones AB, Camp RD, Frodsham A, Browne J, Barber R, Terwilliger J,
Lathrop GM and Barker JN: Identification of a major susceptibility
locus on chromosome 6p and evidence for further disease loci
revealed by a two stage genome-wide search in psoriasis. Hum Mol
Genet. 6:813–820. 1997.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Sagoo GS, Tazi-Ahnini R, Barker JWN, Elder
JT, Nair RP, Samuelsson L, Traupe H, Trembath RC, Robinson DA and
Iles MM: Meta-analysis of genome-wide studies of psoriasis
susceptibility reveals linkage to chromosomes 6p21 and 4q28-q31 in
Caucasian and Chinese Hans population. J Invest Dermatol.
122:1401–1405. 2004.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Chen L and Tsai TF: HLA-Cw6 and psoriasis.
Br J Dermatol. 178:854–862. 2018.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Umapathy S, Pawar A, Mitra R, Khuperkar D,
Devaraj JP, Ghosh K and Khopkar U: Hla-a and Hla-B alleles
associated in psoriasis patients from Mumbai, Western India. Indian
J Dermatol. 56:497–500. 2011.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Nair RP, Duffin KC, Helms C, Ding J,
Stuart PE, Goldgar D, Gudjonsson JE, Li Y, Tejasvi T, Feng BJ, et
al: Genome-wide scan reveals association of psoriasis with IL-23
and NF-kappaB pathways. Nat Genet. 41:199–204. 2009.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Cargill M, Schrodi SJ, Chang M, Garcia VE,
Brandon R, Callis KP, Matsunami N, Ardlie KG, Civello D, Catanese
JJ, et al: A large-scale genetic association study confirms IL12B
and leads to the identification of IL23R as psoriasis-risk genes.
Am J Hum Genet. 80:273–290. 2007.PubMed/NCBI View
Article : Google Scholar
|
|
25
|
Garcia VE, Chang M, Brandon R, Li Y,
Matsunami N, Callis-Duffin KP, Civello D, Rowland CM, Bui N,
Catanese JJ, et al: Detailed genetic characterization of the
interleukin-23 receptor in psoriasis. Genes Immun. 9:546–555.
2008.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Hasegawa H, Mizoguchi I, Chiba Y, Ohashi
M, Xu M and Yoshimoto T: Expanding diversity in molecular
structures and functions of the IL-6/IL-12 heterodimeric cytokine
Family. Front Immunol. 7(479)2016.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Onoufriadis A, Simpson MA, Pink AE, Di
Meglio P, Smith CH, Pullabhatla V, Knight J, Spain SL, Nestle FO,
Burden AD, et al: Mutations in IL36RN/IL1F5 are associated with the
severe episodic inflammatory skin disease known as generalized
pustular psoriasis. Am J Hum Genet. 89:432–437. 2011.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Cullen G, Kroshinsky D, Cheifetz AS and
Korzenik JR: Psoriasis associated with anti-tumour necrosis factor
therapy in inflammatory bowel disease: A new series and a review of
120 cases from the literature. Aliment Pharmacol Ther.
34:1318–1327. 2011.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Pugliese D, Guidi L, Ferraro PM, Marzo M,
Felice C, Celleno L, Landi R, Andrisani G, Pizzolante F, De Vitis
I, et al: Paradoxical psoriasis in a large cohort of patients with
inflammatory bowel disease receiving treatment with anti-TNF alpha:
5-year follow-up study. Aliment Pharmacol Ther. 42:880–888.
2015.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Eickstaedt JB, Killpack L, Tung J, Davis
D, Hand JL and Tollefson MM: Psoriasis and psoriasiform eruptions
in pediatric patients with inflammatory bowel disease treated with
Anti-tumor necrosis factor alpha agents. Pediatr Dermatol.
34:253–260. 2017.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Famenini S and Wu JJ: Infliximab-induced
psoriasis in treatment of Crohn's disease-associated ankylosing
spondylitis: Case report and review of 142 cases. J Drugs Dermatol.
12:939–943. 2013.PubMed/NCBI
|
|
32
|
Filoni A, Vestita M, Congedo M, Giudice G,
Tafuri S and Bonamonte D: Association between psoriasis and vitamin
D: Duration of disease correlates with decreased vitamin D serum
levels: An observational case-control study. Medicine (Baltimore).
97(e11185)2018.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Orgaz-Molina J, Buendía-Eisman A,
Arrabal-Polo MA, Ruiz JC and Arias-Santiago S: Deficiency of serum
concentration of 25-hydroxyvitamin D in psoriatic patients: A
case-control study. J Am Acad Dermatol. 67:931–938. 2012.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Porumb-Andrese E, Vâță D, Postolică R,
Stătescu L, Stătescu C, Grăjdeanu AI, Pătrașcu AI, Popescu IA and
Solovastru LG: Association between personality type, affective
distress profile and quality of life in patients with psoriasis vs.
patients with cardiovascular disease. Exp Ther Med. 18:4967–4973.
2019.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Cai Y, Fleming C and Yan J: New insights
of T cells in the pathogenesis of psoriasis. Cell Mol Immunol.
9:302–309. 2012.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Coimbra S, Figueiredo A, Castro E,
Rocha-Pereira P and Santos-Silva A: The roles of cells and
cytokines in the pathogenesis of psoriasis. Int J Dermatol.
51:389–395. 2012.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Boehncke WH: Etiology and pathogenesis of
psoriasis. Rheum Dis Clin North Am. 41:665–675. 2015.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Lai Y and Gallo RL: AMPed up immunity: How
antimicrobial peptides have multiple roles in immune defense.
Trends Immunol. 30:131–141. 2009.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Ogawa E, Sato Y, Minagawa A and Okuyama R:
Pathogenesis of psoriasis and development of treatment. J Dermatol.
45:264–272. 2018.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Rendon A and Schäkel K: Psoriasis
pathogenesis and treatment. Int J Mol Sci. 20(1475)2019.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Eckert RL, Broome AM, Ruse M, Robinson N,
Ryan D and Lee K: S100 proteins in the epidermis. J Invest
Dermatol. 123:23–33. 2004.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Büchau AS and Gallo RL: Innate immunity
and antimicrobial defense systems in psoriasis. Clin Dermatol.
25:616–624. 2007.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Liang SC, Tan XY, Luxenberg DP, Karim R,
Dunussi-Joannopoulos K, Collins M and Fouser LA: Interleukin
(IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively
enhance expression of antimicrobial peptides. J Exp Med.
203:2271–2279. 2006.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Jinquan T, Vorum H, Larsen CG, Madsen P,
Rasmussen HH, Gesser B, Etzerodt M, Honoré B, Celis JE and
Thestrup-Pedersen K: Psoriasin: A novel chemotactic protein. J
Invest Dermatol. 107:5–10. 1996.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Harder J and Schröder JM: Psoriatic
scales: A promising source for the isolation of human skin-derived
antimicrobial proteins. J Leukoc Biol. 77:476–486. 2005.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Morizane S and Gallo RL: Antimicrobial
peptides in the pathogenesis of psoriasis. J Dermatol. 39:225–230.
2012.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Frohm M, Agerberth B, Ahangari G,
Stâhle-Bäckdahl M, Lidén S, Wigzell H and Gudmundsson G: The
expression of the gene coding for the antibacterial peptide LL-37
is induced in human keratinocytes during inflammatory disorders. J
Biol Chem. 272:15258–15263. 1997.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Lande R, Gregorio J, Facchinetti V,
Chatterjee B, Wang YH, Homey B, Cao W, Wang YH, Su B, Nestle FO, et
al: Plasmacytoid dendritic cells sense self-DNA coupled with
antimicrobial peptide. Nature. 449:564–569. 2007.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Morizane S, Yamasaki K, Mühleisen B, Kotol
PF, Murakami M, Aoyama Y, Iwatsuki K, Hata T and Gallo RL:
Cathelicidin antimicrobial peptide LL-37 in psoriasis enables
keratinocyte reactivity against TLR9 Ligands. J Invest Dermatol.
132:135–143. 2012.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Hänsel A, Günther C, Ingwersen J, Starke
J, Schmitz M, Bachmann M, Meurer M, Rieber EP and Schäkel K: Human
slan (6-sulfo LacNAc) dendritic cells are inflammatory dermal
dendritic cells in psoriasis and drive strong Th17/Th1 T-cell
responses. J Allergy Clin Immunol. 127:787–794.e1-e9.
2011.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Mabuchi T and Hirayama N: Binding affinity
and interaction of LL-37 with HLA-C*06:02 in psoriasis. J Invest
Dermatol. 136:1901–1903. 2016.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Arakawa A, Siewert K, Stöhr J, Besgen P,
Kim SM, Rühl G, Nickel J, Vollmer S, Thomas P, Krebs S, et al:
Melanocyte antigen triggers autoimmunity in human psoriasis. J Exp
Med. 212:2203–2212. 2015.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Krueger JG: An autoimmune ‘attack’ on
melanocytes triggers psoriasis and cellular hyperplasia. J Exp Med.
212:2186. 2015.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Nishimoto S, Kotani H, Tsuruta S, Shimizu
N, Ito M, Shichita T, Morita R, Takahashi H, Amagai M and Yoshimura
A: Th17 cells carrying TCR recognizing epidermal autoantigen induce
psoriasis-like skin inflammation. J Immunol. 191:3065–3072.
2013.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Chiricozzi A, Romanelli P, Volpe E,
Borsellino G and Romanelli M: Scanning the immunopathogenesis of
psoriasis. Int J Mol Sci. 19(E179)2018.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Fuentes-Duculan J, Bonifacio KM, Hawkes
JE, Kunjravia N, Cueto I, Li X, Gonzalez J, Garcet S and Krueger
JG: Autoantigens ADAMTSL5 and LL37 are significantly upregulated in
active Psoriasis and localized with keratinocytes, dendritic cells
and other leukocytes. Exp Dermatol. 26:1075–1082. 2017.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Bonifacio KM, Kunjravia N, Krueger JG and
Duculan JF: Cutaneous expression of A Disintegrin-like and
Metalloprotease domain containing thrombospondin type 1 motif-like
5 (ADAMTSL5) in psoriasis goes beyond Melanocytes. J Pigment
Disord. 3(244)2016.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Liu YJ: IPC: Professional type 1
interferon-producing cells and plasmacytoid dendritic cell
precursors. Annu Rev Immunol. 23:275–306. 2005.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Benhadou F, Mintoff D and Del Marmol V:
Psoriasis: Keratinocytes or immune cells-which is the trigger?
Dermatology. 235:91–100. 2019.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Nestle FO, Conrad C, Tun-Kyi A, Homey B,
Gombert M, Boyman O, Burg G, Liu YJ and Gilliet M: Plasmacytoid
predendritic cells initiate psoriasis through interferon-alpha
production. J Exp Med. 202:135–143. 2005.PubMed/NCBI View Article : Google Scholar
|
|
61
|
van der Fits L, van der Wel LI, Laman JD,
Prens EP and Verschuren MCM: In psoriasis lesional skin the type I
interferon signaling pathway is activated, whereas interferon-alpha
sensitivity is unaltered. J Invest Dermatol. 122:51–60.
2004.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Gilliet M, Conrad C, Geiges M, Cozzio A,
Thürlimann W, Burg G, Nestle FO and Dummer R: Psoriasis triggered
by toll-like receptor 7 agonist imiquimod in the presence of dermal
plasmacytoid dendritic cell precursors. Arch Dermatol.
140:1490–1495. 2004.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Vinter H, Iversen L, Steiniche T,
Kragballe K and Johansen C: Aldara®-induced skin
inflammation: Studies of patients with psoriasis. Br J Dermatol.
172:345–353. 2015.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Takeda K, Kaisho T and Akira S: Toll-like
receptors. Annu Rev Immunol. 21:335–376. 2003.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Honda K, Ohba Y, Yanai H, Negishi H,
Mizutani T, Takaoka A, Taya C and Taniguchi T: Spatiotemporal
regulation of MyD88-IRF-7 signalling for robust type-I interferon
induction. Nature. 434:1035–1040. 2005.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Lande R, Botti E, Jandus C, Dojcinovic D,
Fanelli G, Conrad C, Chamilos G, Feldmeyer L, Marinari B, Chon S,
et al: The antimicrobial peptide LL37 is a T-cell autoantigen in
psoriasis. Nat Commun. 5(5621)2014.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Farkas A and Kemény L: Interferon-α in the
generation of monocyte-derived dendritic cells: Recent advances and
implications for dermatology. Br J Dermatol. 165:247–254.
2011.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Lowes MA, Chamian F, Abello MV,
Fuentes-Duculan J, Lin SL, Nussbaum R, Novitskaya I, Carbonaro H,
Cardinale I, Kikuchi T, et al: Increase in TNF-alpha and inducible
nitric oxide synthase-expressing dendritic cells in psoriasis and
reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci USA.
102:19057–19062. 2005.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Zaba LC, Cardinale I, Gilleaudeau P,
Sullivan-Whalen M, Suárez-Fariñas M, Fuentes-Duculan J, Novitskaya
I, Khatcherian A, Bluth MJ, Lowes MA and Krueger JG: Amelioration
of epidermal hyperplasia by TNF inhibition is associated with
reduced Th17 responses. J Exp Med. 204:3183–3194. 2007.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Zaba LC, Krueger JG and Lowes MA: Resident
and ‘inflammatory’ dendritic cells in human skin. J Invest
Dermatol. 129:302–308. 2009.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Martini E, Wikén M, Cheuk S, Gallais
Sérézal I, Baharom F, Ståhle M, Smed-Sörensen A and Eidsmo L:
Dynamic changes in resident and infiltrating epidermal dendritic
cells in active and resolved psoriasis. J Invest Dermatol.
137:865–873. 2017.PubMed/NCBI View Article : Google Scholar
|
|
72
|
McKenzie BS, Kastelein RA and Cua DJ:
Understanding the IL-23-IL-17 immune pathway. Trends Immunol.
27:17–23. 2006.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Wang F, Lee E, Lowes MA, Haider AS,
Fuentes-Duculan J, Abello MV, Chamian F, Cardinale I and Krueger
JG: Prominent production of IL-20 by CD68+/CD11c+ myeloid-derived
cells in psoriasis: Gene regulation and cellular effects. J Invest
Dermatol. 126:1590–1599. 2006.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Nickoloff BJ: The cytokine network in
psoriasis. Arch Dermatol. 127:871–884. 1991.PubMed/NCBI
|
|
75
|
Reich K, Nestle FO, Papp K, Ortonne JP,
Evans R, Guzzo C, Li S, Dooley LT and Griffiths CE: EXPRESS study
investigators. Infliximab induction and maintenance therapy for
moderate-to-severe psoriasis: A phase III, multicentre,
double-blind trial. Lancet. 366:1367–1374. 2005.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Yao Y, Richman L, Morehouse C, de los
Reyes M, Higgs BW, Boutrin A, White B, Coyle A, Krueger J, Kiener
PA and Jallal B: Type I interferon: Potential therapeutic target
for psoriasis? PLoS One. 3(e2737)2008.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Funk J, Langeland T, Schrumpf E and
Hanssen LE: Psoriasis induced by interferon-alpha. Br J Dermatol.
125:463–465. 1991.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Ketikoglou I, Karatapanis S, Elefsiniotis
I, Kafiri G and Moulakakis A: Extensive psoriasis induced by
pegylated interferon alpha-2b treatment for chronic hepatitis B.
Eur J Dermatol. 15:107–109. 2005.PubMed/NCBI
|
|
79
|
Patel U, Mark NM, Machler BC and Levine
VJ: Imiquimod 5% cream induced psoriasis: A case report, summary of
the literature and mechanism. Br J Dermatol. 164:670–672.
2011.PubMed/NCBI View Article : Google Scholar
|
|
80
|
van der Fits L, Mourits S, Voerman JS,
Kant M, Boon L, Laman JD, Cornelissen F, Mus AM, Florencia E, Prens
EP and Lubberts E: Imiquimod-induced psoriasis-like skin
inflammation in mice is mediated via the IL-23/IL-17 axis. J
Immunol. 182:5836–5845. 2009.PubMed/NCBI View Article : Google Scholar
|
|
81
|
Hida S, Ogasawara K, Sato K, Abe M,
Takayanagi H, Yokochi T, Sato T, Hirose S, Shirai T, Taki S and
Taniguchi T: CD8(+) T cell-mediated skin disease in mice lacking
IRF-2, the transcriptional attenuator of interferon-alpha/beta
signaling. Immunity. 13:643–655. 2000.PubMed/NCBI View Article : Google Scholar
|
|
82
|
Tracey D, Klareskog L, Sasso EH, Salfeld
JG and Tak PP: Tumor necrosis factor antagonist mechanisms of
action: A comprehensive review. Pharmacol Ther. 117:244–279.
2008.PubMed/NCBI View Article : Google Scholar
|
|
83
|
Uyemura K, Yamamura M, Fivenson DF, Modlin
RL and Nickoloff BJ: The cytokine network in lesional and
lesion-free psoriatic skin is characterized by a T-helper type 1
cell-mediated response. J Invest Dermatol. 101:701–705.
1993.PubMed/NCBI View Article : Google Scholar
|
|
84
|
Mocanu M, Toader MP, Rezus E and Taranu T:
Aspects concerning patient adherence to anti-TNFα therapy in
psoriasis: A decade of clinical experience. Exp Ther Med.
18:4987–4992. 2019.PubMed/NCBI View Article : Google Scholar
|
|
85
|
Menter A, Tyring SK, Gordon K, Kimball AB,
Leonardi CL, Langley RG, Strober BE, Kaul M, Gu Y, Okun M and Papp
K: Adalimumab therapy for moderate to severe psoriasis: A
randomized, controlled phase III trial. J Am Acad Dermatol.
58:106–115. 2008.PubMed/NCBI View Article : Google Scholar
|
|
86
|
Papp KA, Tyring S, Lahfa M, Prinz J,
Griffiths CE, Nakanishi AM, Zitnik R, van de Kerkhof PCM and Melvin
L: Etanercept psoriasis study group. A global phase III randomized
controlled trial of etanercept in psoriasis: Safety, efficacy, and
effect of dose reduction. Br J Dermatol. 152:1304–1312.
2005.PubMed/NCBI View Article : Google Scholar
|
|
87
|
Blauvelt A, Reich K, Lebwohl M, Burge D,
Arendt C, Peterson L, Drew J, Rolleri R and Gottlieb AB:
Certolizumab pegol for the treatment of patients with
moderate-to-severe chronic plaque psoriasis: Pooled analysis of
week 16 data from three randomized controlled trials. J Eur Acad
Dermatol Venereol. 33:546–552. 2019.PubMed/NCBI View Article : Google Scholar
|
|
88
|
Lee E, Trepicchio WL, Oestreicher JL,
Pittman D, Wang F, Chamian F, Dhodapkar M and Krueger JG: Increased
expression of interleukin 23 p19 and p40 in lesional skin of
patients with psoriasis vulgaris. J Exp Med. 199:125–130.
2004.PubMed/NCBI View Article : Google Scholar
|
|
89
|
Haider AS, Lowes MA, Suárez-Fariñas M,
Zaba LC, Cardinale I, Khatcherian A, Novitskaya I, Wittkowski KM
and Krueger JG: Identification of cellular pathways of ‘type 1,’
Th17 T cells, and TNF- and inducible nitric oxide
synthase-producing dendritic cells in autoimmune inflammation
through pharmacogenomic study of cyclosporine A in psoriasis. J
Immunol. 180:1913–1920. 2008.PubMed/NCBI View Article : Google Scholar
|
|
90
|
Mahil SK, Capon F and Barker JN: Update on
psoriasis immunopathogenesis and targeted immunotherapy. Semin
Immunopathol. 38:11–27. 2016.PubMed/NCBI View Article : Google Scholar
|
|
91
|
Grechin C, Solovăstru LG, Vâță D, Pătrașcu
AI, Grăjdeanu AI and Porumb-Andrese E: Inflammatory marker
alteration in response to systemic therapies in psoriasis. Exp Ther
Med. 20:42–46. 2020.PubMed/NCBI View Article : Google Scholar
|
|
92
|
Chan JR, Blumenschein W, Murphy E, Diveu
C, Wiekowski M, Abbondanzo S, Lucian L, Geissler R, Brodie S,
Kimball AB, et al: IL-23 stimulates epidermal hyperplasia via TNF
and IL-20R2-dependent mechanisms with implications for psoriasis
pathogenesis. J Exp Med. 203:2577–2587. 2006.PubMed/NCBI View Article : Google Scholar
|
|
93
|
Chamian F, Lowes MA, Lin SL, Lee E,
Kikuchi T, Gilleaudeau P, Sullivan-Whalen M, Cardinale I,
Khatcherian A, Novitskaya I, et al: Alefacept reduces infiltrating
T cells, activated dendritic cells, and inflammatory genes in
psoriasis vulgaris. Proc Natl Acad Sci USA. 102:2075–2080.
2005.PubMed/NCBI View Article : Google Scholar
|
|
94
|
Rizzo HL, Kagami S, Phillips KG, Kurtz SE,
Jacques SL and Blauvelt A: IL-23-mediated psoriasis-like epidermal
hyperplasia is dependent on IL-17A. J Immunol. 186:1495–1502.
2011.PubMed/NCBI View Article : Google Scholar
|
|
95
|
Zheng Y, Danilenko DM, Valdez P, Kasman I,
Eastham-Anderson J, Wu J and Ouyang W: Interleukin-22, a T(H)17
cytokine, mediates IL-23-induced dermal inflammation and
acanthosis. Nature. 445:648–651. 2007.PubMed/NCBI View Article : Google Scholar
|
|
96
|
Tonel G, Conrad C, Laggner U, Di Meglio P,
Grys K, McClanahan TK, Blumenschein WM, Qin JZ, Xin H, Oldham E, et
al: Cutting edge: A critical functional role for IL-23 in
psoriasis. J Immunol. 185:5688–5691. 2010.PubMed/NCBI View Article : Google Scholar
|
|
97
|
Lowes MA, Kikuchi T, Fuentes-Duculan J,
Cardinale I, Zaba LC, Haider AS, Bowman EP and Krueger JG:
Psoriasis vulgaris lesions contain discrete populations of Th1 and
Th17 T cells. J Invest Dermatol. 128:1207–1211. 2008.PubMed/NCBI View Article : Google Scholar
|
|
98
|
Szabo SK, Hammerberg C, Yoshida Y,
Bata-Csorgo Z and Cooper KD: Identification and quantitation of
interferon-gamma Producing T cells in psoriatic lesions:
Localization to Both CD4+ and CD8+ Subsets. J Invest Dermatol.
111:1072–1078. 1998.PubMed/NCBI View Article : Google Scholar
|
|
99
|
Kulig P, Musiol S, Freiberger SN,
Schreiner B, Gyülveszi G, Russo G, Pantelyushin S, Kishihara K,
Alessandrini F, Kündig T, et al: IL-12 protects from psoriasiform
skin inflammation. Nat Commun. 7(13466)2016.PubMed/NCBI View Article : Google Scholar
|
|
100
|
Krueger GG, Langley RG, Leonardi C,
Yeilding N, Guzzo C, Wang Y, Dooley LT and Lebwohl M: CNTO 1275
Psoriasis Study Group. A human interleukin-12/23 monoclonal
antibody for the treatment of psoriasis. N Engl J Med. 356:580–592.
2007.PubMed/NCBI View Article : Google Scholar
|
|
101
|
Lanna C, Mancini M, Gaziano R, Cannizzaro
MV, Galluzzo M, Talamonti M, Rovella V, Annicchiarico-Petruzzelli
M, Melino G, Wang Y, et al: Skin immunity and its dysregulation in
psoriasis. Cell Cycle. 18:2581–2589. 2019.PubMed/NCBI View Article : Google Scholar
|
|
102
|
Nikaein A, Phillips C, Gilbert SC, Savino
D, Silverman A, Stone MJ and Menter A: Characterization of
skin-infiltrating lymphocytes in patients with psoriasis. J Invest
Dermatol. 96:3–9. 1991.PubMed/NCBI View Article : Google Scholar
|
|
103
|
Nickoloff BJ and Wrone-Smith T: Injection
of pre-psoriatic skin with CD4+ T cells induces psoriasis. Am J
Pathol. 155:145–158. 1999.PubMed/NCBI View Article : Google Scholar
|
|
104
|
Gottlieb AB, Lebwohl M, Shirin S, Sherr A,
Gilleaudeau P, Singer G, Solodkina G, Grossman R, Gisoldi E,
Phillips S, et al: Anti-CD4 monoclonal antibody treatment of
moderate to severe psoriasis vulgaris: Results of a pilot,
multicenter, multiple-dose, placebo-controlled study. J Am Acad
Dermatol. 43:595–604. 2000.PubMed/NCBI View Article : Google Scholar
|
|
105
|
Di Cesare A, Di Meglio P and Nestle FO:
The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J
Invest Dermatol. 129:1339–1350. 2009.PubMed/NCBI View Article : Google Scholar
|
|
106
|
Chiricozzi A, Guttman-Yassky E,
Suárez-Fariñas M, Nograles KE, Tian S, Cardinale I, Chimenti S and
Krueger JG: Integrative responses to IL-17 and TNF-α in human
keratinocytes account for key inflammatory pathogenic circuits in
psoriasis. J Invest Dermatol. 131:677–687. 2011.PubMed/NCBI View Article : Google Scholar
|
|
107
|
Harper EG, Guo C, Rizzo H, Lillis JV,
Kurtz SE, Skorcheva I, Purdy D, Fitch E, Iordanov M and Blauvelt A:
Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro
and in vivo: Implications for psoriasis pathogenesis. J Invest
Dermatol. 129:2175–2183. 2009.PubMed/NCBI View Article : Google Scholar
|
|
108
|
Teunissen MB, Koomen CW, de Waal Malefyt
R, Wierenga EA and Bos JD: Interleukin-17 and interferon-gamma
synergize in the enhancement of proinflammatory cytokine production
by human keratinocytes. J Invest Dermatol. 111:645–649.
1998.PubMed/NCBI View Article : Google Scholar
|
|
109
|
Kagami S, Rizzo HL, Lee JJ, Koguchi Y and
Blauvelt A: Circulating Th17, Th22, and Th1 cells are increased in
psoriasis. J Invest Dermatol. 130:1373–1383. 2010.PubMed/NCBI View Article : Google Scholar
|
|
110
|
Tesmer LA, Lundy SK, Sarkar S and Fox DA:
Th17 cells in human disease. Immunol Rev. 223:87–113.
2008.PubMed/NCBI View Article : Google Scholar
|
|
111
|
Priyadarssini M, Divya Priya D, Indhumathi
S, Rajappa M, Chandrashekar L and Thappa DM: Immunophenotyping of T
cells in the peripheral circulation in psoriasis. Br J Biomed Sci.
73:174–179. 2016.PubMed/NCBI View Article : Google Scholar
|
|
112
|
Langley RG, Elewski BE, Lebwohl M, Reich
K, Griffiths CEM, Papp K, Puig L, Nakagawa H, Spelman L,
Sigurgeirsson B, et al: Secukinumab in plaque psoriasis-results of
two phase 3 trials. N Engl J Med. 371:326–338. 2014.PubMed/NCBI View Article : Google Scholar
|
|
113
|
Gordon KB, Blauvelt A, Papp KA, Langley
RG, Luger T, Ohtsuki M, Reich K, Amato D, Ball SG, Braun DK, et al:
Phase 3 trials of Ixekizumab in Moderate-to-Severe plaque
psoriasis. N Engl J Med. 375:345–356. 2016.PubMed/NCBI View Article : Google Scholar
|
|
114
|
Papp KA, Merola JF, Gottlieb AB, Griffiths
CEM, Cross N, Peterson L, Cioffi C and Blauvelt A: Dual
neutralization of both interleukin 17A and interleukin 17F with
bimekizumab in patients with psoriasis: Results from BE ABLE 1, a
12-week randomized, double-blinded, placebo-controlled phase 2b
trial. J Am Acad Dermatol. 79:277–286.e10. 2018.PubMed/NCBI View Article : Google Scholar
|
|
115
|
Lebwohl M, Strober B, Menter A, Gordon K,
Weglowska J, Puig L, Papp K, Spelman L, Toth D, Kerdel F, et al:
Phase 3 studies comparing brodalumab with ustekinumab in psoriasis.
N Engl J Med. 373:1318–1328. 2015.PubMed/NCBI View Article : Google Scholar
|
|
116
|
Blauvelt A: T-Helper 17 cells in psoriatic
plaques and additional genetic links between IL-23 and Psoriasis. J
Invest Dermatol. 128:1064–1067. 2008.PubMed/NCBI View Article : Google Scholar
|
|
117
|
Papp KA, Blauvelt A, Bukhalo M, Gooderham
M, Krueger JG, Lacour JP, Menter A, Philipp S, Sofen H, Tyring S,
et al: Risankizumab versus Ustekinumab for Moderate-to-severe
plaque psoriasis. N Engl J Med. 376:1551–1560. 2017.PubMed/NCBI View Article : Google Scholar
|
|
118
|
Kurzeja M, Rudnicka L and Olszewska M: New
interleukin-23 pathway inhibitors in dermatology: Ustekinumab,
briakinumab, and secukinumab. Am J Clin Dermatol. 12:113–125.
2011.PubMed/NCBI View Article : Google Scholar
|
|
119
|
Alunno A, Carubbi F, Cafaro G, Pucci G,
Battista F, Bartoloni E, Giacomelli R, Schillaci G and Gerli R:
Targeting the IL-23/IL-17 axis for the treatment of psoriasis and
psoriatic arthritis. Expert Opin Biol Ther. 15:1727–1737.
2015.PubMed/NCBI View Article : Google Scholar
|
|
120
|
Papp KA, Menter A, Strober B, Langley RG,
Buonanno M, Wolk R, Gupta P, Krishnaswami S, Tan H and Harness JA:
Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor,
in the treatment of psoriasis: A Phase 2b randomized
placebo-controlled dose-ranging study. Br J Dermatol. 167:668–677.
2012.PubMed/NCBI View Article : Google Scholar
|
|
121
|
Papp K, Gordon K, Thaçi D, Morita A,
Gooderham M, Foley P, Girgis IG, Kundu S and Banerjee S: Phase 2
Trial of selective tyrosine kinase 2 inhibition in psoriasis. N
Engl J Med. 379:1313–1321. 2018.PubMed/NCBI View Article : Google Scholar
|
|
122
|
Papp KA, Menter MA, Raman M, Disch D,
Schlichting DE, Gaich C, Macias W, Zhang X and Janes JM: A
randomized phase 2b trial of baricitinib, an oral Janus kinase
(JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe
psoriasis. Br J Dermatol. 174:1266–1276. 2016.PubMed/NCBI View Article : Google Scholar
|
|
123
|
Murphy KM and Reiner SL: The lineage
decisions of helper T cells. Nat Rev Immunol. 2:933–944.
2002.PubMed/NCBI View
Article : Google Scholar
|
|
124
|
Wei L, Debets R, Hegmans JJ, Benner R and
Prens EP: IL-1 beta and IFN-gamma induce the regenerative epidermal
phenotype of psoriasis in the transwell skin organ culture system.
IFN-gamma up-regulates the expression of keratin 17 and
keratinocyte transglutaminase via endogenous IL-1 production. J
Pathol. 187:358–364. 1999.PubMed/NCBI View Article : Google Scholar
|
|
125
|
Haider AS, Cohen J, Fei J, Zaba LC,
Cardinale I, Toyoko K, Ott J and Krueger JG: Insights into gene
modulation by therapeutic TNF and IFNgamma antibodies: TNF
regulates IFNgamma production by T cells and TNF-regulated genes
linked to psoriasis transcriptome. J Invest Dermatol. 128:655–666.
2008.PubMed/NCBI View Article : Google Scholar
|
|
126
|
Conrad C, Boyman O, Tonel G, Tun-Kyi A,
Laggner U, de Fougerolles A, Kotelianski V, Gardner H and Nestle
FO: Alpha1beta1 integrin is crucial for accumulation of epidermal T
cells and the development of psoriasis. Nat Med. 13:836–842.
2007.PubMed/NCBI View
Article : Google Scholar
|
|
127
|
Ortega C, Fernández-A S, Carrillo JM,
Romero P, Molina IJ, Moreno JC and Santamaría M: IL-17-producing
CD8+ T lymphocytes from psoriasis skin plaques are cytotoxic
effector cells that secrete Th17-related cytokines. J Leukoc Biol.
86:435–443. 2009.PubMed/NCBI View Article : Google Scholar
|
|
128
|
Liang Y, Pan HF and Ye DQ:
IL-17A-producing CD8(+)T cells as therapeutic targets in
autoimmunity. Expert Opin Ther Targets. 19:651–661. 2015.PubMed/NCBI View Article : Google Scholar
|
|
129
|
Opferman JT and Kothari A: Anti-apoptotic
BCL-2 family members in development. Cell Death Differ. 25:37–45.
2018.PubMed/NCBI View Article : Google Scholar
|
|
130
|
Pekarsky Y, Balatti V and Croce CM: BCL2
and miR-15/16: From gene discovery to treatment. Cell Death Differ.
25:21–26. 2018.PubMed/NCBI View Article : Google Scholar
|
|
131
|
Montero J and Letai A: Why do BCL-2
inhibitors work and where should we use them in the clinic? Cell
Death Differ. 25:56–64. 2018.PubMed/NCBI View Article : Google Scholar
|
|
132
|
Rose AM, Sansom OJ and Inman GJ: Loss of
TGF-β signaling drives cSCC from skin stem cells-More evidence.
Cell Cycle. 16:386–387. 2017.PubMed/NCBI View Article : Google Scholar
|
|
133
|
Yuan Y, Ding D, Zhang N, Xia Z, Wang J,
Yang H, Guo F and Li B: TNF-α induces autophagy through ERK1/2
pathway to regulate apoptosis in neonatal necrotizing enterocolitis
model cells IEC-6. Cell Cycle. 17:1390–1402. 2018.PubMed/NCBI View Article : Google Scholar
|
|
134
|
Schlaak JF, Buslau M, Jochum W, Hermann E,
Girndt M, Gallati H, Meyer zum Büschenfelde KH and Fleischer B: T
cells involved in psoriasis vulgaris belong to the Th1 subset. J
Invest Dermatol. 102:145–149. 1994.PubMed/NCBI View Article : Google Scholar
|
|
135
|
Jacob SE, Nassiri M, Kerdel FA and Vincek
V: Simultaneous measurement of multiple Th1 and Th2 serum cytokines
in psoriasis and correlation with disease severity. Mediators
Inflamm. 12:309–313. 2003.PubMed/NCBI View Article : Google Scholar
|
|
136
|
Fierlbeck G, Rassner G and Müller C:
Psoriasis induced at the injection site of recombinant interferon
gamma: Results of immunohistologic investigations. Arch Dermatol.
126:351–355. 1990.PubMed/NCBI
|
|
137
|
Cheuk S, Wikén M, Blomqvist L, Nylén S,
Talme T, Ståhle M and Eidsmo L: Epidermal Th22 and Tc17 cells form
a localized disease memory in clinically healed psoriasis. J
Immunol. 192:3111–3120. 2014.PubMed/NCBI View Article : Google Scholar
|
|
138
|
Lin WJ, Norris DA, Achziger M, Kotzin BL
and Tomkinson B: Oligoclonal expansion of intraepidermal T cells in
psoriasis skin lesions. J Invest Dermatol. 117:1546–1553.
2001.PubMed/NCBI View Article : Google Scholar
|
|
139
|
Takamura S: Niches for the long-term
maintenance of tissue-resident memory T cells. Front Immunol.
9(1214)2018.PubMed/NCBI View Article : Google Scholar
|
|
140
|
Wu H, Liao W, Li Q, Long H, Yin H, Zhao M,
Chan V, Lau CS and Lu Q: Pathogenic role of tissue-resident memory
T cells in autoimmune diseases. Autoimmun Rev. 17:906–911.
2018.PubMed/NCBI View Article : Google Scholar
|
|
141
|
Clark RA, Chong B, Mirchandani N, Brinster
NK, Yamanaka KI, Dowgiert RK and Kupper TS: The vast majority of
CLA+ T cells are resident in normal skin. J Immunol. 176:4431–4439.
2006.PubMed/NCBI View Article : Google Scholar
|
|
142
|
Casey KA, Fraser KA, Schenkel JM, Moran A,
Abt MC, Beura LK, Lucas PJ, Artis D, Wherry EJ, Hogquist K, et al:
Antigen-independent differentiation and maintenance of
effector-like resident memory T cells in tissues. J Immunol.
188:4866–4875. 2012.PubMed/NCBI View Article : Google Scholar
|
|
143
|
Mackay LK, Rahimpour A, Ma JZ, Collins N,
Stock AT, Hafon ML, Vega-Ramos J, Lauzurica P, Mueller SN,
Stefanovic T, et al: The developmental pathway for CD103(+)CD8+
tissue-resident memory T cells of skin. Nat Immunol. 14:1294–1301.
2013.PubMed/NCBI View Article : Google Scholar
|
|
144
|
Owczarczyk Saczonek A,
Krajewska-Włodarczyk M, Kasprowicz-Furmańczyk M and Placek W:
Immunological memory of psoriatic lesions. Int J Mol Sci.
21(625)2020.PubMed/NCBI View Article : Google Scholar
|
|
145
|
Milner JJ and Goldrath AW: Transcriptional
programming of tissue-resident memory CD8+ T cells. Curr Opin
Immunol. 51:162–169. 2018.PubMed/NCBI View Article : Google Scholar
|
|
146
|
Eberle FC, Brück J, Holstein J, Hirahara K
and Ghoreschi K: Recent advances in understanding psoriasis.
F1000Res. 5(F1000 Faculty Rev-770)2016.PubMed/NCBI View Article : Google Scholar
|
|
147
|
Patra V, Laoubi L, Nicolas JF, Vocanson M
and Wolf P: A Perspective on the interplay of
ultraviolet-radiation, skin microbiome and skin resident memory
TCRαβ+ cells. Front Med (Lausanne). 5(166)2018.PubMed/NCBI View Article : Google Scholar
|
|
148
|
Clark RA: Resident memory T cells in human
health and disease. Sci Transl Med. 7(269rv1)2015.PubMed/NCBI View Article : Google Scholar
|
|
149
|
Mueller SN, Zaid A and Carbone FR:
Tissue-Resident T Cells: Dynamic players in skin immunity. Front
Immunol. 5(332)2014.PubMed/NCBI View Article : Google Scholar
|
|
150
|
Corgnac S, Boutet M, Kfoury M, Naltet C
and Mami-Chouaib F: The Emerging Role of CD8+ tissue resident
memory T (TRM) cells in antitumor immunity: A unique functional
contribution of the CD103 integrin. Front Immunol.
9(1904)2018.PubMed/NCBI View Article : Google Scholar
|
|
151
|
Kurihara K, Fujiyama T, Phadungsaksawasdi
P, Ito T and Tokura Y: Significance of IL-17A-producing CD8+CD103+
skin resident memory T cells in psoriasis lesion and their possible
relationship to clinical course. J Dermatol Sci. 95:21–27.
2019.PubMed/NCBI View Article : Google Scholar
|
|
152
|
Walsh D, Borges da Silva H, Beura L, Peng
C, Hamilton S, Masopust D and Jameson S: The functional requirement
for CD69 in establishment of resident memory CD8 + T cells varies
with tissue location. J Immunol. 203:946–955. 2019.PubMed/NCBI View Article : Google Scholar
|
|
153
|
Mackay LK, Braun A, Macleod BL, Collins N,
Tebartz C, Bedoui S, Carbone FR and Gebhardt T: Cutting edge: CD69
interference with sphingosine-1-phosphate receptor function
regulates peripheral T cell retention. J Immunol. 194:2059–2063.
2015.PubMed/NCBI View Article : Google Scholar
|
|
154
|
Schenkel JM and Masopust D:
Tissue-resident memory T cells. Immunity. 41:886–897.
2014.PubMed/NCBI View Article : Google Scholar
|
|
155
|
Cheuk S, Schlums H, Gallais Sérézal I,
Martini E, Chiang SC, Marquardt N, Gibbs A, Detlofsson E, Introini
A, Forkel M, et al: CD49a expression defines Tissue-resident CD8+ T
cells poised for cytotoxic function in human skin. Immunity.
46:287–300. 2017.PubMed/NCBI View Article : Google Scholar
|
|
156
|
Seidel JA, Vukmanovic-Stejic M,
Muller-Durovic B, Patel N, Fuentes-Duculan J, Henson SM, Krueger
JG, Rustin MHA, Nestle FO, Lacy KE and Akbar AN: Skin resident
memory CD8+ T cells are phenotypically and functionally
distinct from circulating populations and lack immediate cytotoxic
function. Clin Exp Immunol. 194:79–92. 2018.PubMed/NCBI View Article : Google Scholar
|
|
157
|
Petrelli A and van Wijk F: CD8(+) T cells
in human autoimmune arthritis: The unusual suspects. Nat Rev
Rheumatol. 12:421–428. 2016.PubMed/NCBI View Article : Google Scholar
|
|
158
|
Ritchlin C: Tissue-resident memory T
cells: Sequestered immune sensors and effectors of inflammation in
Spondyloarthritis. Arthritis Rheumatol. 72:379–382. 2020.PubMed/NCBI View Article : Google Scholar
|
|
159
|
Adachi T, Kobayashi T, Sugihara E, Yamada
T, Ikuta K, Pittaluga S, Saya H, Amagai M and Nagao K: Hair
follicle-derived IL-7 and IL-15 mediate skin-resident memory T cell
homeostasis and lymphoma. Nat Med. 21:1272–1279. 2015.PubMed/NCBI View Article : Google Scholar
|
|
160
|
Diani M, Galasso M, Cozzi C, Sgambelluri
F, Altomare A, Cigni C, Frigerio E, Drago L, Volinia S, Granucci F,
et al: Blood to skin recirculation of CD4+ memory T cells
associates with cutaneous and systemic manifestations of psoriatic
disease. Clin Immunol. 180:84–94. 2017.PubMed/NCBI View Article : Google Scholar
|
|
161
|
Matos TR, O'Malley JT, Lowry EL, Hamm D,
Kirsch IR, Robins HS, Kupper TS, Krueger JG and Clark RA:
Clinically resolved psoriatic lesions contain psoriasis-specific
IL-17-producing αβ T cell clones. J Clin Invest. 127:4031–4041.
2017.PubMed/NCBI View Article : Google Scholar
|
|
162
|
Meglio PD, Villanova F, Navarini AA,
Mylonas A, Tosi I, Nestle FO and Conrad C: Targeting CD8+ T cells
prevents psoriasis development. J Allergy Clin Immunol.
138:274–276.e6. 2016.PubMed/NCBI View Article : Google Scholar
|
|
163
|
Farber DL, Yudanin NA and Restifo NP:
Human memory T cells: Generation, compartmentalization and
homeostasis. Nat Rev Immunol. 14:24–35. 2014.PubMed/NCBI View Article : Google Scholar
|
|
164
|
Boyman O, Hefti HP, Conrad C, Nickoloff
BJ, Suter M and Nestle FO: Spontaneous development of psoriasis in
a new animal model shows an essential role for resident T cells and
tumor necrosis Factor-alpha. J Exp Med. 199:731–736.
2004.PubMed/NCBI View Article : Google Scholar
|
|
165
|
Campbell JJ, Clark RA, Watanabe R and
Kupper TS: Sezary syndrome and mycosis fungoides arise from
distinct T-cell subsets: A biologic rationale for their distinct
clinical behaviors. Blood. 116:767–771. 2010.PubMed/NCBI View Article : Google Scholar
|
|
166
|
Gallais Sérézal I, Classon C, Cheuk S,
Barrientos-Somarribas M, Wadman E, Martini E, Chang D, Landén NX,
Ehrström M, Nylén S and Eidsmo L: Resident T cells in resolved
psoriasis steer tissue responses that stratify clinical outcome. J
Invest Dermatol. 138:1754–1763. 2018.PubMed/NCBI View Article : Google Scholar
|
|
167
|
Sérézal IG, Hoffer E, Ignatov B, Martini
E, Zitti B, Ehrström M and Eidsmo L: A skewed pool of resident T
cells triggers psoriasis-associated tissue responses in
never-lesional skin from patients with psoriasis. J Allergy Clin
Immunol. 143:1444–1454. 2019.PubMed/NCBI View Article : Google Scholar
|
|
168
|
Vo S, Watanabe R, Koguchi-Yoshioka H,
Matsumura Y, Ishitsuka Y, Nakamura Y, Okiyama N, Fujisawa Y and
Fujimoto M: CD8 resident memory T cells with interleukin
17A-producing potential are accumulated in disease-naïve
nonlesional sites of psoriasis possibly in correlation with disease
duration. Br J Dermatol. 181:410–412. 2019.PubMed/NCBI View Article : Google Scholar
|
|
169
|
Diani M, Altomare G and Reali E: T Helper
cell subsets in clinical manifestations of psoriasis. J Immunol
Res. 2016(e7692024)2016.PubMed/NCBI View Article : Google Scholar
|
|
170
|
Bosè F, Petti L, Diani M, Moscheni C,
Molteni S, Altomare A, Rossi RL, Talarico D, Fontana R, Russo V, et
al: Inhibition of CCR7/CCL19 axis in lesional skin is a critical
event for clinical remission induced by TNF blockade in patients
with psoriasis. Am J Pathol. 183:413–421. 2013.PubMed/NCBI View Article : Google Scholar
|
|
171
|
Watanabe R: Protective and pathogenic
roles of resident memory T cells in human skin disorders. J
Dermatol Sci. 95:2–7. 2019.PubMed/NCBI View Article : Google Scholar
|
|
172
|
Sgambelluri F, Diani M, Altomare A,
Frigerio E, Drago L, Granucci F, Banfi G, Altomare G and Reali E: A
role for CCR5(+)CD4 T cells in cutaneous psoriasis and for CD103(+)
CCR4(+) CD8 Teff cells in the associated systemic inflammation. J
Autoimmun. 70:80–90. 2016.PubMed/NCBI View Article : Google Scholar
|
|
173
|
Chen L and Shen Z: Tissue-resident memory
T cells and their biological characteristics in the recurrence of
inflammatory skin disorders. Cell Mol Immunol. 17:64–75.
2020.PubMed/NCBI View Article : Google Scholar
|
|
174
|
Pan Y and Kupper TS: Metabolic
reprogramming and longevity of tissue-resident memory T cells.
Front Immunol. 9(1347)2018.PubMed/NCBI View Article : Google Scholar
|
|
175
|
Pearce EL, Walsh MC, Cejas PJ, Harms GM,
Shen H, Wang LS, Jones RG and Choi Y: Enhancing CD8 T-cell memory
by modulating fatty acid metabolism. Nature. 460:103–107.
2009.PubMed/NCBI View Article : Google Scholar
|
|
176
|
Cui G, Staron MM, Gray SM, Ho PC,
Amezquita RA, Wu J and Kaech SM: IL-7-induced glycerol transport
and TAG synthesis promotes memory CD8+ T cell longevity. Cell.
161:750–761. 2015.PubMed/NCBI View Article : Google Scholar
|
|
177
|
Pan Y, Tian T, Park CO, Lofftus SY, Mei S,
Liu X, Luo C, O'Malley JT, Gehad A, Teague JE, et al: Survival of
tissue-resident memory T cells requires exogenous lipid uptake and
metabolism. Nature. 543:252–256. 2017.PubMed/NCBI View Article : Google Scholar
|
|
178
|
Esmaeili B, Mansouri P, Doustimotlagh AH
and Izad M: Redox imbalance and IL-17 responses in memory
CD4+ T cells from patients with psoriasis. Scand J
Immunol. 89(e12730)2019.PubMed/NCBI View Article : Google Scholar
|
|
179
|
Karamehic J, Zecevic L, Resic H, Jukic M,
Jukic T, Ridjic O, Panjeta M and Coric J: Immunophenotype
lymphocyte of peripheral blood in patients with psoriasis. Med
Arch. 68:236–238. 2014.PubMed/NCBI View Article : Google Scholar
|
